These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
458 related articles for article (PubMed ID: 23785172)
1. The use of O-(2-18F-fluoroethyl)-L-tyrosine PET for treatment management of bevacizumab and irinotecan in patients with recurrent high-grade glioma: a cost-effectiveness analysis. Heinzel A; Müller D; Langen KJ; Blaum M; Verburg FA; Mottaghy FM; Galldiks N J Nucl Med; 2013 Aug; 54(8):1217-22. PubMed ID: 23785172 [TBL] [Abstract][Full Text] [Related]
2. O-(2-18F-fluoroethyl)-L-tyrosine PET predicts failure of antiangiogenic treatment in patients with recurrent high-grade glioma. Hutterer M; Nowosielski M; Putzer D; Waitz D; Tinkhauser G; Kostron H; Muigg A; Virgolini IJ; Staffen W; Trinka E; Gotwald T; Jacobs AH; Stockhammer G J Nucl Med; 2011 Jun; 52(6):856-64. PubMed ID: 21622893 [TBL] [Abstract][Full Text] [Related]
3. Response assessment of bevacizumab in patients with recurrent malignant glioma using [18F]Fluoroethyl-L-tyrosine PET in comparison to MRI. Galldiks N; Rapp M; Stoffels G; Fink GR; Shah NJ; Coenen HH; Sabel M; Langen KJ Eur J Nucl Med Mol Imaging; 2013 Jan; 40(1):22-33. PubMed ID: 23053325 [TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness analysis of FET PET-guided target selection for the diagnosis of gliomas. Heinzel A; Stock S; Langen KJ; Müller D Eur J Nucl Med Mol Imaging; 2012 Jul; 39(7):1089-96. PubMed ID: 22419257 [TBL] [Abstract][Full Text] [Related]
5. O-(2-18F-fluoroethyl)-L-tyrosine PET for evaluation of brain metastasis recurrence after radiotherapy: an effectiveness and cost-effectiveness analysis. Heinzel A; Müller D; Yekta-Michael SS; Ceccon G; Langen KJ; Mottaghy FM; Wiesmann M; Kocher M; Hattingen E; Galldiks N Neuro Oncol; 2017 Sep; 19(9):1271-1278. PubMed ID: 28204572 [TBL] [Abstract][Full Text] [Related]
6. Prognostic Value of O-(2-[18F]-Fluoroethyl)-L-Tyrosine-Positron Emission Tomography Imaging for Histopathologic Characteristics and Progression-Free Survival in Patients with Low-Grade Glioma. Bette S; Gempt J; Delbridge C; Kirschke JS; Schlegel J; Foerster S; Huber T; Pyka T; Zimmer C; Meyer B; Ringel F World Neurosurg; 2016 May; 89():230-9. PubMed ID: 26855307 [TBL] [Abstract][Full Text] [Related]
7. Role of O-(2-18F-fluoroethyl)-L-tyrosine PET as a diagnostic tool for detection of malignant progression in patients with low-grade glioma. Galldiks N; Stoffels G; Ruge MI; Rapp M; Sabel M; Reifenberger G; Erdem Z; Shah NJ; Fink GR; Coenen HH; Langen KJ J Nucl Med; 2013 Dec; 54(12):2046-54. PubMed ID: 24159047 [TBL] [Abstract][Full Text] [Related]
8. Cost Effectiveness of Rosen J; Ceccon G; Bauer EK; Werner JM; Tscherpel C; Dunkl V; Rapp M; Sabel M; Herrlinger U; Heinzel A; Schäfer N; Ruge M; Goldbrunner R; Stoffels G; Kabbasch C; Fink GR; Langen KJ; Galldiks N J Nucl Med; 2022 Nov; 63(11):1677-1682. PubMed ID: 35422443 [TBL] [Abstract][Full Text] [Related]
10. The diagnostic accuracy of detecting malignant transformation of low-grade glioma using O-(2-[18F]fluoroethyl)-l-tyrosine positron emission tomography: a retrospective study. Bashir A; Brennum J; Broholm H; Law I J Neurosurg; 2018 Apr; 130(2):451-464. PubMed ID: 29624154 [TBL] [Abstract][Full Text] [Related]
11. Comparison of O-(2- Verger A; Filss CP; Lohmann P; Stoffels G; Sabel M; Wittsack HJ; Kops ER; Galldiks N; Fink GR; Shah NJ; Langen KJ World Neurosurg; 2018 May; 113():e727-e737. PubMed ID: 29510293 [TBL] [Abstract][Full Text] [Related]
12. The use of dynamic O-(2-18F-fluoroethyl)-l-tyrosine PET in the diagnosis of patients with progressive and recurrent glioma. Galldiks N; Stoffels G; Filss C; Rapp M; Blau T; Tscherpel C; Ceccon G; Dunkl V; Weinzierl M; Stoffel M; Sabel M; Fink GR; Shah NJ; Langen KJ Neuro Oncol; 2015 Sep; 17(9):1293-300. PubMed ID: 26008606 [TBL] [Abstract][Full Text] [Related]
13. Comparison of 18F-FET PET and perfusion-weighted MR imaging: a PET/MR imaging hybrid study in patients with brain tumors. Filss CP; Galldiks N; Stoffels G; Sabel M; Wittsack HJ; Turowski B; Antoch G; Zhang K; Fink GR; Coenen HH; Shah NJ; Herzog H; Langen KJ J Nucl Med; 2014 Apr; 55(4):540-5. PubMed ID: 24578243 [TBL] [Abstract][Full Text] [Related]